

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

THE MEDICINES COMPANY,	)	
	)	
Plaintiff,	)	
	)	
v.	)	C.A. No. _____
	)	
PLIVA HRVATSKA d.o.o.,	)	
PLIVA d.d.,	)	
BARR LABORATORIES, INC.,	)	
BARR PHARMACEUTICALS, INC.,	)	
BARR PHARMACEUTICALS, LLC,	)	
TEVA PHARMACEUTICALS USA, INC.	)	
and TEVA PHARMACEUTICAL	)	
INDUSTRIES, LTD.	)	
	)	
Defendants.	)	

**COMPLAINT**

Plaintiff The Medicines Company, by its undersigned attorneys, for its Complaint against defendants Pliva Hrvatska d.o.o. (“Pliva Hrvatska”); Pliva d.d.; Barr Laboratories, Inc. (“Barr Labs”); Barr Pharmaceuticals, Inc. and Barr Pharmaceuticals, LLC (collectively “Barr Pharmaceuticals”); Teva Pharmaceuticals USA, Inc. (“Teva USA”); and Teva Pharmaceutical Industries, Ltd. (“Teva Ltd.”) (collectively “Defendants” or “Pliva/Barr”) alleges as follows:

**NATURE OF THE ACTION**

1. This is an action for patent infringement arising under the patent laws of the United States, Title 35, United States Code, involving United States Patent No. 7,598,343 (“the ’343 patent”) (attached as Exhibit A hereto).

**THE PARTIES**

2. Plaintiff The Medicines Company is a corporation organized and existing under the laws of the State of Delaware, having a place of business at 8 Sylvan Way, Parsippany, New Jersey 07054.

3. Upon information and belief, Teva Ltd. is a corporation organized and existing under the laws of Israel, with a principal place of business at 5 Basel Street, Petah Tikva, Israel. Upon information and belief, Teva Ltd. is in the business of developing, manufacturing, marketing, and selling generic drugs throughout the world, including throughout the United States including the State of Delaware.

4. Upon information and belief, Teva USA is a corporation organized and existing under the laws of the State of Delaware, with a principal place of business at 1090 Horsham Road, North Wales, Pennsylvania 19454.

5. Upon information and belief, Teva USA is a wholly-owned subsidiary of Teva Ltd. Upon information and belief, Teva USA is controlled and/or dominated by Teva Ltd. Upon information and belief, Teva Ltd. and Teva USA have at least one officer and/or director in common.

6. Upon information and belief, Teva USA manufactures and distributes generic drugs for sale and use throughout the United States, including at the direction of, under the control of, and for the direct benefit of Teva Ltd. Upon information and belief, Teva USA acts as the U.S. agent for Teva Ltd. for purposes of regulatory submissions to the U.S. Food and Drug Administration (“FDA”) seeking approval for generic drugs. Upon information and belief, Teva USA acts as the U.S. sales and marketing agent for Teva Ltd. for generic drugs.

7. Upon information and belief, Barr Pharmaceuticals is an entity organized and existing under the laws of the State of Delaware, with a principal place of business at 400 Chestnut Ridge Road, Woodcliff Lake, New Jersey 07677.

8. Upon information and belief, Barr Pharmaceuticals is a wholly-owned subsidiary of Teva Ltd. Upon information and belief, Barr Pharmaceuticals is controlled and/or dominated by Teva Ltd.

9. Upon information and belief, Barr Labs is a corporation organized and existing under the laws of the State of Delaware, with a principal place of business at 400 Chestnut Ridge Road, Woodcliff Lake, New Jersey 07677.

10. Upon information and belief, Barr Labs is a wholly-owned subsidiary of Barr Pharmaceuticals. Upon information and belief, Barr Labs is controlled and/or dominated by Barr Pharmaceuticals and/or Teva Ltd. Upon information and belief, Barr Labs and Barr Pharmaceuticals have at least one officer and/or director in common.

11. Upon information and belief, Barr Labs manufactures and distributes generic drugs for sale and use throughout the United States, including at the direction of, under the control of, and for the direct benefit of Barr Pharmaceuticals and Teva Ltd.

12. Upon information and belief, Pliva d.d. is a corporation organized and existing under the laws of Croatia, with a principal place of business at Ulica grada Vukovara 49, 1000 Zagreb, Croatia. Upon information and belief, Pliva d.d. is in the business of developing, manufacturing, marketing, and selling generic drugs throughout the world, including throughout the United States including the State of Delaware.

13. Upon information and belief, Pliva d.d. is a wholly-owned subsidiary of Barr Pharmaceuticals. Upon information and belief, Pliva d.d. is controlled and/or dominated by Barr Pharmaceuticals and/or Teva Ltd. Upon information and belief, Pliva d.d. and Barr Pharmaceuticals have at least one officer and/or director in common.

14. Upon information and belief, Pliva Hrvatska is a corporation organized and existing under the laws of Croatia, with a principal place of business at Ulica grada Vukovara 49, 1000 Zagreb, Croatia. Upon information and belief, Pliva Hrvatska is in the business of developing, manufacturing, marketing, and selling generic drugs throughout the world, including throughout the United States including the State of Delaware.

15. Upon information and belief, Pliva Hrvatska is a wholly-owned subsidiary of Pliva d.d. Upon information and belief, Pliva Hrvatska is controlled and/or dominated by Pliva d.d., Barr Pharmaceuticals and/or Teva Ltd.

16. Upon information and belief, Barr Labs acts as the U.S. agent for Pliva Hrvatska and Pliva d.d. for purposes of regulatory submissions to the FDA seeking approval for certain generic drugs, including injectable generic drugs.

17. Upon information and belief, Pliva Hrvatska and/or Pliva d.d. manufacture and supply certain generic drugs, including injectable generic drugs, to Barr Labs, which acts as the U.S. sales and marketing agent for Pliva Hrvatska and/or Pliva d.d.

**JURISDICTION AND VENUE**

18. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a).

19. This Court has personal jurisdiction over Teva Ltd. because, *inter alia*, of its continuous and systematic contacts with the State of Delaware by virtue of directly and/or through its wholly-owned subsidiaries, manufacturing, marketing and selling drugs throughout the United States, including the State of Delaware, and therefore has availed itself of the privilege of conducting business within the State of Delaware.

20. This Court has personal jurisdiction over Teva USA. Teva USA has submitted to personal jurisdiction in this Court because, *inter alia*, it is a resident and citizen of the State of Delaware and has availed itself to the rights and benefits of the laws of Delaware by virtue of incorporating in Delaware.

21. This Court has personal jurisdiction over Barr Pharmaceuticals. Barr Pharmaceuticals has submitted to personal jurisdiction in this Court because, *inter alia*, it is a resident and citizen of the State of Delaware and has availed itself to the rights and benefits of the laws of Delaware by virtue of incorporating in Delaware.

22. This Court has personal jurisdiction over Barr Labs. Barr Labs has submitted to personal jurisdiction in this Court because, *inter alia*, it is a resident and citizen of the State of Delaware and has availed itself to the rights and benefits of the laws of Delaware by virtue of incorporating in Delaware.

23. This Court has personal jurisdiction over Pliva d.d. because, *inter alia*, of its continuous and systematic contacts with the State of Delaware by virtue of directly and/or through its parent company, manufacturing, marketing and selling drugs throughout the United States, including the State of Delaware, and therefore has availed itself of the privilege of

conducting business within the State of Delaware.

24. This Court has personal jurisdiction over Pliva Hrvatska because, *inter alia*, of its continuous and systematic contacts with the State of Delaware by virtue of directly and/or through its parent company, manufacturing, marketing and selling drugs throughout the United States, including the State of Delaware, and therefore has availed itself of the privilege of conducting business within the State of Delaware.

25. Venue is proper in this judicial district under 28 U.S.C. §§ 1391(b) and (c), and § 1400(b).

#### **FACTS AS TO ALL COUNTS**

26. The Medicines Company is the owner of New Drug Application (“NDA”) No. 20-873, which was approved by the FDA for the manufacture and sale of Angiomax®. Angiomax® is the trade name for bivalirudin, 250 mg/vial, for intravenous injection for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty.

27. The ’343 patent, entitled “Pharmaceutical formulations of bivalirudin and processes of making the same,” was duly and legally issued on October 6, 2009, to The Medicines Company upon assignment from Gopal Krishna and Gary Musso. The ’343 patent is generally directed to bivalirudin compositions.

28. Pursuant to 21 U.S.C. § 355(b)(1), the ’343 patent is listed in FDA’s publication entitled “Approved Drug Products with Therapeutic Equivalence Evaluations” (commonly known as the “*Orange Book*”) as covering The Medicines Company’s Angiomax® product.

29. Pliva Hrvatska and Barr Labs, Pliva Hrvatska's U.S. agent, prepared and submitted Abbreviated New Drug Application ("ANDA") No. 91-206 ("Pliva's ANDA") to the FDA under § 505(j) of the FDCA seeking approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation of generic bivalirudin, 250 mg/vial, for intravenous injection ("Pliva's Proposed Product").

30. On behalf of Pliva Hrvatska, Pliva d.d., Barr Pharmaceuticals, Teva USA and Teva Ltd., Barr Labs sent The Medicines Company a notification for the '343 patent purportedly pursuant to § 505(j)(2)(B)(ii) of the FDCA regarding Pliva's Proposed Product ("Pliva's Notice Letter").

31. 21 U.S.C. § 355(j)(2)(B)(iv)(II) requires that a letter notifying a patent holder of the filing of an ANDA containing a paragraph IV certification "include a detailed statement of the factual and legal basis of the opinion of the applicant that the patent is invalid or will not be infringed." Likewise, 21 C.F.R. § 314.95(c)(6) requires a paragraph IV notification to include "[a] detailed statement of the factual and legal basis of applicant's opinion that the patent is not valid, unenforceable, or will not be infringed." The detailed statement is to include "(i) [f]or each claim of a patent alleged not to be infringed, a full and detailed explanation of why the claim is not infringed" and "(ii) [f]or each claim of a patent alleged to be invalid or unenforceable, a full and detailed explanation of the grounds supporting the allegation." 21 C.F.R. §§ 314.95(c)(6)(i)-(ii).

32. Despite 21 U.S.C. § 355(j)(5)(C)(i)(III), Pliva's Notice Letter did not contain an Offer of Confidential Access to Pliva's ANDA.

33. Pliva had previously sent The Medicines Company a notification for U.S. Patent No. 7,582,727 (“the ’727 patent”) purportedly pursuant to § 505(j)(2)(B)(ii) of the FDCA regarding Pliva’s Proposed Product. On October 8, 2009, The Medicines Company brought an action for patent infringement involving the ’727 patent in a related case: *The Medicines Company v. Pliva Hrvatska d.o.o.*, 09-cv-751 (ECR) (D. Del.).

**FIRST COUNT**

(Infringement of the ’343 Patent by Pliva Hrvatska, Pliva d.d.,  
Barr Labs, Barr Pharmaceuticals, Teva USA and Teva Ltd.)

34. The Medicines Company repeats and realleges each of the foregoing paragraphs as if fully set forth herein.

35. Upon information and belief, Pliva Hrvatska seeks FDA-approval for the manufacture and/or distribution of Pliva’s Proposed Product.

36. Upon information and belief, Pliva Hrvatska and Barr Labs amended Pliva’s ANDA to include a paragraph IV certification to the ’343 patent to obtain approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation of Pliva’s Proposed Product before the expiration of the ’343 patent.

37. Upon information and belief, Pliva Hrvatska, Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and/or Teva Ltd. will commercially manufacture, sell, offer for sale, and/or import Pliva’s Proposed Product immediately upon FDA-approval. Upon information and belief, Pliva Hrvatska, Barr Labs, Teva USA and Teva Ltd. expect to receive final FDA-approval on or about September 23, 2010.

38. Upon information and belief, as of the date of Pliva’s Notice Letter, Pliva Hrvatska, Barr Labs, Teva USA and Teva Ltd. were aware of the statutory provisions and regulations set forth in 21 U.S.C. § 355(j)(2)(B)(iv)(II) and 21 C.F.R. § 314.95(c)(6).



39. The amendment of ANDA No. 91-206 with a paragraph IV certification to the '343 patent for the purpose of obtaining approval to engage in the commercial manufacture, use, sale, offer for sale and/or importation of Pliva's Proposed Product before the expiration of the '343 patent is an act of infringement by Pliva Hrvatska and Barr Labs of one or more claims of the '343 patent under 35 U.S.C. § 271(e)(2)(A).

40. Upon information and belief, Pliva Hrvatska's, Pliva d.d.'s, Barr Labs', Barr Pharmaceuticals', Teva USA's and/or Teva Ltd.'s commercial manufacture, use, sale, offer for sale and/or importation into the United States of Pliva's Proposed Product that is the subject of ANDA No. 91-206 will infringe one or more claims of the '343 patent.

41. Upon information and belief, Pliva Hrvatska, Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and Teva Ltd. are aware of the existence of the '343 patent and acted without a reasonable basis for believing that it would not be liable for infringement of the '343 patent, thus rendering this case "exceptional" under 35 U.S.C. § 285.

42. The acts of infringement set forth above will cause The Medicines Company irreparable harm for which it has no adequate remedy at law, unless Pliva Hrvatska, Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and Teva Ltd. are preliminarily and permanently enjoined by this Court.

**SECOND COUNT**

(Induced and/or Contributory Infringement of the '343 Patent  
by Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and Teva Ltd.)

43. The Medicines Company repeats and realleges each of the foregoing paragraphs as if fully set forth herein.

44. Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and Teva Ltd. are jointly and severally liable for Pliva Hrvatska's infringement of one or more claims of the '343 patent.

45. Pliva Hrvatska, Pliva d.d., Barr Pharmaceuticals, Teva USA and Teva Ltd. are jointly and severally liable for Barr Labs' infringement of one or more claims of the '343 patent.

46. Upon information and belief, Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and Teva Ltd. knowingly induced Pliva Hrvatska to infringe and/or contributed to Pliva Hrvatska's infringement of one or more claims of the '343 patent.

47. Upon information and belief, Pliva Hrvatska, Pliva d.d., Barr Pharmaceuticals, Teva USA and Teva Ltd. knowingly induced Barr Labs to infringe and/or contributed to Barr Labs' infringement of one or more claims of the '343 patent.

48. Upon information and belief, Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and Teva Ltd. actively induced, encouraged, aided, or abetted Pliva Hrvatska's amendment of ANDA No. 91-206 with a paragraph IV certification to the '343 patent.

49. Upon information and belief, Pliva Hrvatska, Pliva d.d., Barr Pharmaceuticals, Teva USA and Teva Ltd. actively induced, encouraged, aided, or abetted Barr Labs' preparation and submission of ANDA No. 91-206 and amendment with a paragraph IV certification to the '343 patent.

50. Pliva d.d.'s, Barr Labs', Barr Pharmaceuticals', Teva USA's and Teva Ltd.'s inducement, encouragement, aiding, or abetting of Pliva Hrvatska's preparation and submission of ANDA No. 91-206 and amendment with a paragraph IV certification constitutes infringement of the '727 patent under 35 U.S.C. § 271(e)(2)(A).

51. Pliva Hrvatska's, Pliva d.d.'s, Barr Pharmaceuticals', Teva USA's and Teva Ltd.'s inducement, encouragement, aiding, or abetting of Barr Labs' amendment of ANDA No. 91-206 with a paragraph IV certification constitutes infringement of the '343 patent under 35 U.S.C. § 271(e)(2)(A).

52. Further Pliva d.d.'s, Barr Labs', Barr Pharmaceuticals', Teva USA's and Teva Ltd.'s commercial use, sale, offer for sale and/or importation of Pliva's Proposed Product would induce and/or contribute to Pliva Hrvatska's infringement of the '343 patent under 35 U.S.C. § 271(b) and/or 35 U.S.C. § 271(c).

53. Further Pliva Hrvatska's, Pliva d.d.'s, Barr Pharmaceuticals', Teva USA's and Teva Ltd.'s commercial use, sale, offer for sale and/or importation of Pliva's Proposed Product would induce and/or contribute to Barr Labs' infringement of the '343 patent under 35 U.S.C. § 271(b) and/or 35 U.S.C. § 271(c).

54. Upon information and belief, Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and Teva Ltd. have, continue to, and will actively induce, encourage, aid, or abet Pliva's infringement of the '343 patent with knowledge that it is in contravention of The Medicines Company's rights.

55. Upon information and belief, Pliva Hrvatska, Pliva d.d., Barr Pharmaceuticals, Teva USA and Teva Ltd. have, continue to, and will actively induce, encourage, aid, or abet Barr Labs' infringement of the '343 patent with knowledge that it is in contravention of The Medicines Company's rights.

56. Upon information and belief, Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and Teva Ltd. are aware of the existence of the '343 patent and acted without a reasonable basis for believing that it would not be liable for inducing and/or contributing to Pliva Hrvatska's infringement of the '343 patent, thus rendering this case "exceptional" under 35 U.S.C. § 285.

57. Upon information and belief, Pliva Hrvatska, Pliva d.d., Barr Pharmaceuticals, Teva USA and Teva Ltd. are aware of the existence of the '343 patent and acted without a reasonable basis for believing that it would not be liable for inducing and/or contributing to Barr Labs' infringement of the '343 patent, thus rendering this case "exceptional" under 35 U.S.C. § 285.

58. The acts of infringement set forth above will cause The Medicines Company irreparable harm for which it has no adequate remedy at law, unless Pliva Hrvatska, Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and Teva Ltd. are preliminarily and permanently enjoined by this Court.

**PRAYER FOR RELIEF**

WHEREFORE, Plaintiff respectfully requests the following relief:

- (a) A judgment declaring that the '343 patent is valid and enforceable;
- (b) A judgment declaring that, pursuant to 35 U.S.C. § 271(e)(2)(A), the submission to the FDA of ANDA No. 91-206 with a paragraph IV certification amendment to obtain approval for the commercial manufacture, use, sale, offer for sale and/or importation in the United States of the product that is the subject of ANDA No. 91-206 was an act of infringement of the '343 patent by Pliva Hrvatska and Barr Labs, individually and collectively;

(c) A judgment declaring that, pursuant to 35 U.S.C. § 271(e)(2)(A) and/or 35 U.S.C. § 271(a), the commercial manufacture, use, sale, offer for sale and/or importation in the United States of the product that is the subject of ANDA No. 91-206 prior to the expiration of the '343 patent, including any regulatory extensions, will constitute an act of infringement by Pliva Hrvatska, Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and Teva Ltd., individually and collectively;

(d) A judgment declaring that, pursuant to 35 U.S.C. § 271(e)(2)(A), Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and Teva Ltd. has and continues to induce and/or contribute to Pliva Hrvatska's infringement of the '343 patent based on the submission to the FDA of ANDA No. 91-206 with a paragraph IV certification amendment to obtain approval for the commercial manufacture, use, sale, offer for sale and/or importation in the United States of the product that is the subject of ANDA No. 91-206;

(e) A judgment declaring that, pursuant to 35 U.S.C. § 271(e)(2)(A), Pliva Hrvatska, Pliva d.d., Barr Pharmaceuticals, Teva USA and Teva Ltd. have and continue to induce and/or contribute to Barr Lab's infringement of the '343 patent based on the submission to the FDA of ANDA No. 91-206 with a paragraph IV certification amendment to obtain approval for the commercial manufacture, use, sale, offer for sale and/or importation in the United States of the product that is the subject of ANDA No. 91-206;

(f) A judgment declaring that, pursuant to 35 U.S.C. § 271(b) and/or 35 U.S.C. § 271(c), Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and Teva Ltd. would induce and/or contribute to Pliva Hrvatska's infringement of the '343 patent based on the commercial manufacture, use, sale, offer for sale and/or importation in the United States of the product that is the subject of ANDA No. 91-206;

(g) A judgment declaring that, pursuant to 35 U.S.C. § 271(b) and/or 35 U.S.C. § 271(c), Pliva Hrvatska, Pliva d.d., Barr Pharmaceuticals, Teva USA and Teva Ltd. would induce and/or contribute to Barr Labs' infringement of the '343 patent based on the commercial manufacture, use, sale, offer for sale and/or importation in the United States of the product that is the subject of ANDA No. 91-206;

(h) An order that, pursuant to 35 U.S.C. § 271(e)(4)(A), the effective date of any approval of the product that is the subject of ANDA No. 91-206 shall be no earlier than the date on which the '343 patent expires including any regulatory extensions;

(i) A judgment pursuant to 35 U.S.C. § 271(e)(4)(B) preliminarily and permanently enjoining Pliva Hrvatska, Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA, Teva Ltd., their officers, agents, servants, employees and attorneys, and those persons in active concert or participation or privity with them or any of them, from engaging in the commercial manufacture, use, sale, offer to sale and/or importation in the United States of the product that is the subject of ANDA No. 91-206 until the expiration of the '343 patent including any regulatory extensions;

(j) A judgment awarding The Medicines Company damages or other monetary relief, pursuant to 35 U.S.C. §§ 271(e)(4)(C) and 284, if Pliva Hrvatska, Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and/or Teva Ltd. commercially manufacture, use, sell, offer to sell and/or import any product that is the subject of ANDA No. 91-206 that infringes the '343 patent;

(k) A judgment declaring that infringement of the '343 patent is willful if Pliva Hrvatska, Pliva d.d., Barr Labs, Barr Pharmaceuticals, Teva USA and/or Teva Ltd. commercially manufacture, use, sell, offer to sell and/or import any product that is the subject of ANDA No. 91-206 that infringes the '343 patent;

(l) A judgment declaring that, pursuant to 35 U.S.C. § 285, this is an exceptional case and awarding The Medicines Company its attorneys' fees and costs;

(m) Such other and further relief as this Court may deem just and proper.

*Of Counsel*

Edgar H. Haug  
Porter F. Fleming  
Angus Chen  
Frommer Lawrence & Haug LLP  
745 Fifth Avenue  
New York, NY 10151  
(212) 588-0800

Dated: December 28, 2009



Frederick L. Cottrell, III (#2555)  
cottrell@rlf.com  
Laura D. Hatcher (#5098)  
hatcher@rlf.com  
Richards, Layton & Finger P.A.  
One Rodney Square  
920 N. King Street  
Wilmington, DE 19801  
(302) 651-7700

*Attorneys for Plaintiff  
The Medicines Company*